中国生物技术Antengene提出2025年ACR CD19目标疗法ATG-201的临床预科数据,预计2025年晚些时候进行临床试验。 Chinese biotech Antengene to present preclinical data on CD19-targeted therapy ATG-201 at ACR 2025, with clinical trials expected late 2025.

中国生物技术Antengene将在10月24日至29日在芝加哥举行的2025年ACR年会上提供ATG-201的临床预科数据,该ATG-201是用于自发免疫疾病的CD19目标T细胞诱导器。 Chinese biotech Antengene will present preclinical data on ATG-201, a CD19-targeted T-cell engager for autoimmune diseases, at the 2025 ACR Annual Meeting in Chicago from October 24 to 29. ATG-201在其AnTenGager TCE平台上开发,使用“2+1”装订设计,以提高安全和效能,并有可能在自动免疫条件、固态肿瘤和血癌方面应用。 Developed on its AnTenGager TCE platform, ATG-201 uses a "2+1" binding design to improve safety and efficacy, with potential applications across autoimmune conditions, solid tumors, and blood cancers. 预计该疗法将在2025年底进入临床试验阶段。 The therapy is expected to enter clinical trials in late 2025. Antengene在美国和亚洲获得了31份IND批准,并在11个亚太市场提交了NDA。 Antengene has secured 31 IND approvals in the U.S. and Asia and submitted NDAs in 11 Asia Pacific markets.